secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-09-22T12:00:40+00:00
Accession:  0001171843-26-006161
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Filana's simufilam, enabling Phase 2a trial for TSC-related epilepsy
--------------------------------------------------------------------------------

- FDA lifted full clinical hold on Filana's IND for simufilam on Sept 22, 2026, enabling Phase 2a trial in TSC-related epilepsy.
- Phase 2a trial: 16-week, randomized, double-blind, two doses, 13 U.S. sites, target 40 subjects aged 12-55; screening expected Q1 2027.
- Company completed trial-readiness during hold: engaged leading CRO, identified sites, recruiting investigators, drug supply in place.
- TSC Alliance CEO Kari Luther Rosbeck praised work; simufilam reduced seizure frequency in two preclinical mouse models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326006161/0001171843-26-006161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326006161/f8k_092226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-006161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer